Publications by authors named "L Cuthbertson"
Long-term outcomes of kidney replacement therapy in Australians with prune belly syndrome.
J Paediatr Child Health
December 2024
Article Synopsis
- * A total of 37 males with PBS were analyzed, with most starting KRT in their teens; half underwent kidney transplants, showing good graft survival rates at 1, 5, and 10 years.
- * The findings indicated that while there was variation in individual outcomes for PBS patients, their overall transplant and dialysis survival rates were similar or better than those of the control group.
Domestic animals are common in Australian households; however, there is little research into the potential risks these animals pose to patients undergoing in-home peritoneal dialysis (PD). Cats and dogs are known to carry many potential pathogens, including . We reviewed the ANZDATA Peritoneal Dialysis Peritonitis Registry for cases of peritonitis due to between 2011 and 2023.
View Article and Find Full Text PDFBackground: Patient-centred measurement (PCM) emphasizes a holistic approach wherein the voices of patients are reflected in the standardized use of patient-reported outcome and experience measures and are represented throughout the continuum of measurement activities. Given the challenges of routinely integrating patient self-reports into clinical care decisions, the perspectives of all healthcare system stakeholders, especially patients, is necessary to advance the science of PCM. The purpose of the analysis we report on here was to identify patient-driven research priorities for advancing the science of PCM.
View Article and Find Full Text PDFObjective: DR/ER-MPH (formerly HLD200) is an evening-dosed delayed-release and extended-release methylphenidate approved for the treatment of ADHD in patients ≥6 years. analyses of two pivotal Phase 3 trials: HLD200-107 (NCT02493777) and HLD200-108 (NCT02520388) evaluated emotional lability (EL) with DR/ER-MPH treatment.
Methods: Differences in Conners Global Index-Parent (CGI-P) EL subscale scores and age- and gender-adjusted -scores over an open-label titration phase (HLD200-107) and between treatment and placebo groups at endpoint (HLD200-108) were evaluated.